Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BiomX ( (PHGE) ) just unveiled an update.
On August 19, 2025, BiomX Inc. announced that the FDA has placed a clinical hold on its Phase 2b study for the drug candidate BX004, intended for treating Cystic Fibrosis, due to a review of data on a third-party nebulizer used in the study. While the FDA did not express concerns about BX004 itself, the hold has paused patient screening and enrollment in the U.S., though the study continues in Europe where the nebulizer components meet regulatory requirements.
The most recent analyst rating on (PHGE) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on BiomX stock, see the PHGE Stock Forecast page.
Spark’s Take on PHGE Stock
According to Spark, TipRanks’ AI Analyst, PHGE is a Neutral.
BiomX’s overall score is driven by significant financial challenges, including negative revenues and high leverage, which are key risks. However, recent positive trial results and funding announcements provide potential for future growth and improvement.
To see Spark’s full report on PHGE stock, click here.
More about BiomX
BiomX Inc. operates in the biotechnology industry, focusing on developing innovative treatments for chronic diseases. The company is primarily engaged in creating phage therapies, with a significant emphasis on addressing conditions like Cystic Fibrosis.
Average Trading Volume: 5,090,349
Technical Sentiment Signal: Sell
Current Market Cap: $14.81M
Find detailed analytics on PHGE stock on TipRanks’ Stock Analysis page.